TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37153087

Group type: EXPERIMENTAL
Intervention: Bee venom (BV) phonophoresis with conservative treatment of medical ulcer care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment of medical ulcer care with ultrasound sessions only (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bee venom (BV) phonophoresis
Number of subjects: 100
Study: 37153102

Group type: EXPERIMENTAL
Intervention: Multidimensional group intervention including Memory Compensatory Strategies, Problem-Solving, Emotion Regulation, Mindfulness, and Locus of Control.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multidimensional group intervention.
Number of subjects: 30
Study: 37153118

Group type: EXPERIMENTAL
Intervention: Same-day initiation of HIV treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard initiation of HIV treatment
Number of subjects: 0
Study: 37153145

Group type: EXPERIMENTAL
Intervention: TAF (20mg)/EVG (16mg) vaginal insert
Number of subjects: 16
Study: 37153587

Group type: EXPERIMENTAL
Intervention: serplulimab 4.5 mg/kg plus nab-paclitaxel 260 mg/m² for up to 2 years (35 dosing cycles)
Number of subjects: 21
Study: 37153702

Group type: EXPERIMENTAL
Intervention: Intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray, 16 to 24 IU 3 times daily at mealtimes)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (excipient-matched)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intranasal OXT
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 37153751

Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37153770

Group type: EXPERIMENTAL
Intervention: Low-dose combined olanzapine and sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37153876

Group type: EXPERIMENTAL
Intervention: Daratumumab monotherapy
Number of subjects: 0
Study: 37154020

Group type: EXPERIMENTAL
Intervention: 10 mg of oral rivaroxaban daily for 35 days
Number of subjects: 1284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1284
Study: 37154412

Group type: EXPERIMENTAL
Intervention: ACLR + ALLR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isolated ACLR
Number of subjects: 80
Study: 37154471

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 37154608

Group type: EXPERIMENTAL
Intervention: Stromal Cells, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 37154609

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study: 37154888

Group type: EXPERIMENTAL
Intervention: Diabetes Survival Skills (DSS) intervention (6-week, 1-h per week)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 37154986

Group type: EXPERIMENTAL
Intervention: Visensia Safety Index (VSI)
Number of subjects: 1529

Group type: COMPARATOR
Intervention: Periodic Early Warning Score (EWS)
Number of subjects: 1529

Group type: COMPARATOR
Intervention: Stable patients
Number of subjects: 1529
Study: 37155004

Group type: EXPERIMENTAL
Intervention: Dronedarone for 3 months after radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0
Study: 37155132

Group type: EXPERIMENTAL
Intervention: Diroximel Fumarate (DRF)
Number of subjects: 2190
Study: 37155164

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-informed treatment (PIT) with TCAs (nortriptyline, clomipramine, or imipramine) based on CYP2D6 and CYP2C19 genotypes.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual treatment with standard initial TCA dosage.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-informed treatment (PIT)
Number of subjects: 111
Study: 37155171

Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine plus Digital Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 37155168

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C for 72 hours)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control (rectal temperatures maintained between 36.0 °C and 37.0 °C)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control
Number of subjects: 408
Study: 37155223

Group type: EXPERIMENTAL
Intervention: HIV e-report
Number of subjects: 357
Study: 37155240

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 2408

Group type: COMPARATOR
Intervention: Web-based notification platform
Number of subjects: 2408
Study: 37155264

Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: BWL
Number of subjects: 0
Study: 37155342

Group type: EXPERIMENTAL
Intervention: Anlotinib plus PD-1 inhibitor
Number of subjects: 41
Study: 37155596

Group type: EXPERIMENTAL
Intervention: HBB Prompt mobile application
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no HBB Prompt)
Number of subjects: 29
Study: 37155645

Group type: EXPERIMENTAL
Intervention: Isocaloric, energy-restricted ketogenic diet (KD) for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, balanced diet with the same calorie content
Number of subjects: 0
Study: 37155710

Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37155976

Group type: EXPERIMENTAL
Intervention: Self-management energy conservation intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 19
Study: 37156007

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment of fractures
Number of subjects: 31
Study: 37156249

Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 plus chemotherapy (pemetrexed and cisplatin)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 476

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 plus chemotherapy
Number of subjects: 476
Study: 37156252

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 582

Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 582
Study: 37156318

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 61
Study: 37156373

Group type: EXPERIMENTAL
Intervention: Exercise plus usual care
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 21
Study: 37156426

Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing (CAMI)
Number of subjects: 149
Study: 37156466

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg (up to 100 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Weight categories (≤90 kg: 40 mg; 91-130 kg: 60 mg; 131-170 kg: 80 mg; >170 kg: 100 mg)
Number of subjects: 124
Study: 37156551

Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with NY-ESO-1-specific TCR transgenic lymphocytes, NY-ESO-1 peptide-pulsed dendritic cell (DC) vaccination, and nivolumab-mediated PD-1 blockade
Number of subjects: 1

Group type: COMPARATOR
Intervention: Nivolumab-mediated PD-1 blockade
Number of subjects: 1
Study: 37156575

Group type: EXPERIMENTAL
Intervention: Citizen Science intervention implemented in intervention schools for 6 months.
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group (high schools not receiving the intervention).
Number of subjects: 720
Study: 37156577

Group type: EXPERIMENTAL
Intervention: Keeping in Touch (KiT) text message-based intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 183
Study: 37156585

Group type: EXPERIMENTAL
Intervention: Bubble-PAPR
Number of subjects: 91

Group type: COMPARATOR
Intervention: FFP3
Number of subjects: 91
Study: 37156587

Group type: EXPERIMENTAL
Intervention: Home-based guided hypnotherapy via a website for 3 months (intervention group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Care as usual (CAU) by their GP (control group)
Number of subjects: 200
Study: 37156588

Group type: EXPERIMENTAL
Intervention: Shortened antibiotic treatment of 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic treatment of 7 days or longer
Number of subjects: 0
Study: 37156670

Group type: EXPERIMENTAL
Intervention: High tissue sodium accumulation
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-obese individuals
Number of subjects: 83
Study: 37156782

Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, and dexamethasone (Isa-Kd)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 302
Study: 37156960

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation in community pharmacy or by phone
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 229
Study: 37157110

Group type: EXPERIMENTAL
Intervention: Large change intervention
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Small change intervention
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control
Number of subjects: 599
Study: 37157126

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 142
Study: 37158010

Group type: EXPERIMENTAL
Intervention: Illness anxiety (worry about illness, bodily preoccupation)
Number of subjects: 8148

Group type: EXPERIMENTAL
Intervention: Vaccine willingness
Number of subjects: 8148

Group type: EXPERIMENTAL
Intervention: Duration of the pandemic
Number of subjects: 8148

Group type: EXPERIMENTAL
Intervention: Infection rates
Number of subjects: 8148

Group type: EXPERIMENTAL
Intervention: Higher illness anxiety
Number of subjects: 8148
Study: 37158042

Group type: EXPERIMENTAL
Intervention: Quality education intervention
Number of subjects: 13
Study: 37158083

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy, details not available
Number of subjects: 0
Study: 37158104

Group type: EXPERIMENTAL
Intervention: Immediate multivessel PCI
Number of subjects: 315

Group type: COMPARATOR
Intervention: Culprit-only PCI
Number of subjects: 315
Study: 37158145

Group type: EXPERIMENTAL
Intervention: Surgeons experiencing severe complications after radical gastrectomy
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Surgeons from non-university affiliated hospitals, junior surgeons, and those facing violent doctor-patient conflicts
Number of subjects: 1062
Study: 37158157

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Operator experience
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Learning curve for avoiding major complications
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Learning curve for avoiding poor outcomes
Number of subjects: 217
Study: 37158171

Group type: EXPERIMENTAL
Intervention: hs-cTnI 0/1-hour algorithm
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: hs-cTnI 0/3-hour algorithm
Number of subjects: 3523

Group type: COMPARATOR
Intervention: hs-cTnI
Number of subjects: 3523

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 3523
Study: 37158245

Group type: EXPERIMENTAL
Intervention: Microdosing via the Optejet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37158447

Group type: EXPERIMENTAL
Intervention: Calibrated blood-collection drape and treatment bundle (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, and escalation)
Number of subjects: 210132

Group type: EXPERIMENTAL
Intervention: Calibrated blood-collection drape and treatment bundle
Number of subjects: 210132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210132
Study: 37158538

Group type: EXPERIMENTAL
Intervention: Combined pharmacologic and psychosocial interventions
Number of subjects: 17626

Group type: COMPARATOR
Intervention: Pharmacologic intervention alone
Number of subjects: 17626

Group type: COMPARATOR
Intervention: Psychosocial interventions alone
Number of subjects: 17626

Group type: COMPARATOR
Intervention: Pharmacologic in addition to psychosocial intervention
Number of subjects: 17626
Study: 37158751

Group type: EXPERIMENTAL
Intervention: semaglutide (subcutaneously once per week) for 26 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 5
Study: 37158780

Group type: EXPERIMENTAL
Intervention: Virtual 'Coping with Brain Fog' intervention, details on dosage and duration not available
Number of subjects: 0
Study: 37158831

Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg for 17 or 26 weeks
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg for 17 or 26 weeks
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg for 17 or 26 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standardized six-month treatment regimen (rifampicin, isoniazid, pyrazinamide, ethambutol for 26 weeks)
Number of subjects: 400
Study: 37158872

Group type: EXPERIMENTAL
Intervention: Motivation Matters! mHealth intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 119
Study: 37158911

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo nasal spray plus an oral antidepressant (AD + PBO)
Number of subjects: 223
Study: 37158925

Group type: EXPERIMENTAL
Intervention: Probiotics treatment for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 80
Study: 37158929

Group type: EXPERIMENTAL
Intervention: General order set improvements
Number of subjects: 0

Group type: COMPARATOR
Intervention: General order set improvements plus non-interruptive in-line help text alert
Number of subjects: 0

Group type: COMPARATOR
Intervention: General order set improvements plus interruptive alert
Number of subjects: 0

Group type: COMPARATOR
Intervention: All arms of the study in aggregate
Number of subjects: 0
Study: 37158938

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) administered intravenously every 3 weeks
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in NSCLC
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in NPC
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in CC
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in colorectal cancer
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in small cell lung cancer
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 in immunotherapy-naive patients
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (10 mg/kg) in phase I
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) overall
Number of subjects: 518
Study: 37158965

Group type: EXPERIMENTAL
Intervention: Site-specific HCV treatment workflows utilizing direct-acting antivirals (DAAs) and a simplified treatment algorithm.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews guided by the Practical, Robust Implementation and Sustainability Model (PRISM) framework.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of providers on the use of a simplified HCV treatment algorithm with DAAs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation and clinical outcomes measured through interviews and medical chart review.
Number of subjects: 0
Study: 37158990

Group type: EXPERIMENTAL
Intervention: Teplizumab (Tzield), a monoclonal antibody
Number of subjects: 0
Study: 37159035

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate combined with prednisolone
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo combined with prednisolone
Number of subjects: 292
Study: 37159034

Group type: EXPERIMENTAL
Intervention: 600 mg of ziritaxestat
Number of subjects: 1306

Group type: EXPERIMENTAL
Intervention: 200 mg of ziritaxestat
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1306
Study: 37159195

Group type: EXPERIMENTAL
Intervention: Lactulose ingestion (20 g) during a continuous 10-hour sodium d3-acetate intravenous infusion
Number of subjects: 44

Group type: COMPARATOR
Intervention: OIR group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lean group
Number of subjects: 44

Group type: COMPARATOR
Intervention: OIS group
Number of subjects: 44
Study: 37159200

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 37159245

Group type: EXPERIMENTAL
Intervention: 2-way texting (2wT)
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 1084
Study: 37159251

Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still water (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red Bull energy drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Still water
Number of subjects: 0
Study: 37159264

Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) 1,000 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Coenzyme Q10 (CoQ10) 1,200 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) and Coenzyme Q10 (CoQ10)
Number of subjects: 25
Study: 37159269

Group type: EXPERIMENTAL
Intervention: THA (Total Hip Arthroplasty)
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Charnley Class C (multiple-joint OA)
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Older age
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Four or more comorbidities
Number of subjects: 3411
Study: 37159276

Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%) in Responders (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%) in Non-responders (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%)
Number of subjects: 43
Study: 37159610

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 177
Study: 37160281

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.8 × 10^6 or 2.7 × 10^6 doses administered via direct venous inoculation at 8-week intervals)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 207
Study: 37160394

Group type: EXPERIMENTAL
Intervention: 'Do Not Do' recommendations with possible gender bias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative research techniques (consensus conference and nominal group)
Number of subjects: 0
Study: 37160396

Group type: EXPERIMENTAL
Intervention: Ride-on-toy navigation training (RNT) programme, provided 4-5 times/week for 30-45 min/session over 6 weeks, in addition to conventional therapy.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional therapy alone during the 6-week control phase.
Number of subjects: 15
Study: 37160401

Group type: COMPARATOR
Intervention: Anticholinergic drugs
Number of subjects: 47106
Study: 37160439

Group type: EXPERIMENTAL
Intervention: Iodine 123 labeled meta-iodobenzylguanidine
Number of subjects: 40
Study: 37160552

Group type: EXPERIMENTAL
Intervention: Mild-moderate IC group
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Severe IC group
Number of subjects: 839
Study: 37160576

Group type: EXPERIMENTAL
Intervention: Ambulatory visit with a cardiologist
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Older age, higher body mass index (BMI), atrial fibrillation, multimorbidity, urban residence, and no recent insurance
Number of subjects: 2039

Group type: EXPERIMENTAL
Intervention: Diagnosed CVD, insurance type, and urban residence
Number of subjects: 2039
Study: 37160787

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM), n=50
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG), n=50
Number of subjects: 100
Study: 37160808

Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic Roux-en-Y reconstruction
Number of subjects: 0
Study: 37160822

Group type: EXPERIMENTAL
Intervention: Pain management strategies (pain scales, pain diaries, liaison with research team)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Educational content regarding postoperative care
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies (acetaminophen and ibuprofen)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Communication with healthcare providers
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: General parental experience
Number of subjects: 317
Study: 37160872

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study: 37161345

Group type: EXPERIMENTAL
Intervention: Self-administered computerized mental health screening tool
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group (no computerized screening reports)
Number of subjects: 451
Study: 37161369

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation
Number of subjects: 197

Group type: COMPARATOR
Intervention: Facemask ventilation
Number of subjects: 197